Penumbra, Inc. reported significant financial growth in its latest 10-K filing, with total revenue reaching $1.4 billion for the year ended December 31, 2025, marking a 17.5% increase from $1.2 billion in 2024. The company's income from operations also saw a substantial rise, climbing to $189.2 million compared to $9.3 million in the previous year. This growth was primarily driven by increased sales of both thrombectomy and embolization products, with thrombectomy revenue alone increasing by 16.2% to $947.9 million, while embolization and access products grew by 20.2% to $455.7 million.
The filing highlighted a strategic shift as Penumbra exited its immersive healthcare business, which resulted in a $115.3 million impairment charge in 2024. No further charges related to this exit were reported in 2025, indicating a clean break from that segment. Additionally, on January 14, 2026, Penumbra announced a merger agreement with Boston Scientific Corporation, valuing the company at approximately $14.5 billion. Under the terms of the agreement, shareholders can choose to receive $374 in cash or shares of Boston Scientific stock, with the merger expected to close by the end of 2026, pending regulatory approvals.
Operationally, Penumbra's workforce expanded to approximately 4,700 employees as of December 31, 2025, reflecting the company's growth strategy. The company reported that direct sales accounted for about 90% of its revenue, with significant contributions from both domestic and international markets. The U.S. market represented 77.8% of total revenue, while international sales accounted for 22.2%, showing a slight decline from the previous year. The company continues to focus on expanding its product offerings and market penetration, particularly in the thrombectomy and embolization sectors.
Looking ahead, Penumbra's management expressed optimism about future growth, emphasizing the importance of product innovation and market expansion. The company plans to continue investing in research and development to enhance its product portfolio and maintain competitive advantages in the medical device industry. However, the filing also noted potential risks, including reliance on key suppliers, regulatory challenges, and the competitive landscape, which could impact future performance. The company remains committed to navigating these challenges while pursuing its strategic objectives.
About Penumbra Inc
Penumbra, Inc. develops innovative medical devices for treating vascular and neurovascular conditions, including thrombectomy, embolization, and access products. Its portfolio targets stroke, pulmonary embolism, aneurysms, and other blood vessel disorders, primarily serving healthcare providers worldwide. The company emphasizes proprietary technology, regulatory compliance, and clinical research to deliver safe, effective, and cost-efficient solutions in endovascular therapy.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.